Skip to content

Eloralintide ResearchScience today. A healthier tomorrow.

Ask the site

Evidence-graded, provenance-first

A reference on Eloralintide, built to show its work.

The science. The results. The bigger picture.

Eloralintide (LY3841136) is an investigational, long-acting amylin-receptor agonist in clinical development. Every claim here carries an evidence tier and a source, and verified findings, preliminary signals and open questions are kept clearly apart.

Explore the clinical evidence How we grade evidence

More than a molecule.
A bigger conversation.

Explore by Topic

View All Articles

Clinical TrialsMechanism of ActionComparisonsSafety & Side EffectsTesting & PurityLatest News

Topic artwork is conceptual. It does not show real data or molecular structures.

Better questions lead to better science, and a healthier tomorrow.

Combination research

Different pathways. One bigger question.

Eloralintide is studied on its own and alongside tirzepatide. Lilly’s Phase 2b trial combined amylin biology with GLP-1 and GIP biology, and reported a greater mean weight reduction with the combination than with tirzepatide alone.

Eloralintide vs tirzepatidePhase 2b readout

23.3%Eloralintide + tirzepatide

14.8%Tirzepatide alone

48 weeks · Phase 2b · obesity or overweight with type 2 diabetes
Mean weight reduction as reported by Lilly (9 mg + 15 mg vs 15 mg). Not peer-reviewed.

Analytical science

Know what your Eloralintide test actually proves.

Understand identity, purity, quantity and structural testing, and learn how to check the evidence behind a report.

  • Identity
  • Purity
  • Quantity
  • Structure

Read the Eloralintide verification guide

Eloralintide is investigational and not approved. Educational information, not medical advice.

Latest research

  1. Lilly reports Phase 2b results for eloralintide plus tirzepatide in obesity with type 2 diabetes

    -23.3% vs -14.8%Mean weight change at 48 weeks: eloralintide 9 mg plus tirzepatide 15 mg vs tirzepatide 15 mg alone

    Combination
  2. Cardiology in Review article asks whether eloralintide’s early cardiometabolic effects could matter for heart risk
    Mechanism
  3. Lilly previews its EASD 2026 program, including an amylins in diabetes symposium for eloraTZP

    17% vs 10%Weight loss over 16 weeks, eloralintide 3 mg plus tirzepatide 5 mg vs tirzepatide 5 mg alone, as stated by Lilly (Phase 1)

    Combination
  4. Pharmacological Research review examines why amylin-based drugs cause nausea, and how that might be reduced
    Mechanism

View all research news

The full reference

Every section, one standard of evidence

Eloralintide

What it is, its development status, and how the evidence on this site is graded.

Pillar overview

Clinical Development

Phase I, the 48-week Phase II trial, and the Phase III ENLIGHTEN program.

Phase I, II, III and the trials index

Mechanism and Molecule

Amylin biology, AMY1R selectivity, the engineered structure, and half-life.

4 pages

Comparisons

Cross-trial methodology first, then cagrilintide and tirzepatide.

Methodology and comparisons

Analytical Science

What testing can and cannot prove. HPLC, NMR and mass spectrometry.

Methods library

Metabolic Research Landscape

Where eloralintide sits among the other compounds now in obesity-research development.

Pipeline overview and 4 compound profiles

Research News

Registry updates, publications and program milestones, dated as they happen.

Latest updates

Clinical development snapshot

Live trial status

Trial records

A trial registration shows that a study exists. It does not show that the compound works, is safe, or has been approved, and recruitment says nothing about the eventual result.

Phase II, 48-week obesity trial

Phase IICompleted(confirmed 2026-10-01 via ClinicalTrials.gov; primary completion 2025-05-30, completion 2025-08-14)

Registry NCT06230523

Adults with obesity or overweight without type 2 diabetes

Last verified

ENLIGHTEN-2

Phase IIIRecruiting(confirmed 2026-10-01 via ClinicalTrials.gov; primary completion 2028-01, completion 2028-02)

Registry NCT07282600

Adults with obesity or overweight with type 2 diabetes

Last verified

ENLIGHTEN-1

Phase IIIRecruiting(confirmed 2026-10-01 via ClinicalTrials.gov; primary completion 2028-03, completion 2030-07)

Registry NCT07321886

Adults with obesity or overweight without type 2 diabetes

Last verified

ENLIGHTEN-4

Phase IIIRecruiting(confirmed 2026-10-01 via ClinicalTrials.gov; primary completion 2028-03, completion 2028-05)

Registry NCT07353931

Adults with knee osteoarthritis pain and obesity or overweight

Last verified

ENLIGHTEN-3

Phase IIIRecruiting(confirmed 2026-10-01 via ClinicalTrials.gov; primary completion 2028-03, completion 2028-04). EU CT number 2025-523769-11-00: authorised and recruiting in Germany and Spain per the EU Clinical Trials Information System, checked 2026-10-01

Registry NCT07369011

Adults with moderate-to-severe obstructive sleep apnea and obesity or overweight

Last verified

ENLIGHTEN-6

Phase IIIRecruiting(confirmed 2026-10-01 via ClinicalTrials.gov; primary completion 2028-06, completion 2028-07)

Registry NCT07392190

Adults with persistent obesity or overweight on stable weekly incretin therapy

Last verified

Phase I, hepatic impairment pharmacokinetic study

Phase IRecruiting(confirmed 2026-10-01 via ClinicalTrials.gov; primary completion and completion 2027-03)

Registry NCT07401862

Participants with mild, moderate or severe hepatic impairment and participants with normal hepatic function

Last verified

Phase I, renal impairment pharmacokinetic study

Phase IActive, not recruiting(confirmed 2026-10-01 via ClinicalTrials.gov; primary completion and completion 2026-10)

Registry NCT07426380

Participants with severe renal impairment or end-stage kidney disease on hemodialysis, and participants with normal renal function

Last verified

Phase I, insulin sensitivity study

Phase IRecruiting(confirmed 2026-10-01 via ClinicalTrials.gov; primary completion and completion 2027-08)

Registry NCT07665879

Adults with overweight or obesity

Last verified

Phase I, gastric emptying study

Phase IRecruiting(confirmed 2026-10-01 via ClinicalTrials.gov; primary completion and completion 2026-12)

Registry NCT07738614

Adults with obesity or overweight

Last verified

Phase I, oral contraceptive interaction study

Phase INot yet recruiting(confirmed 2026-10-01 via ClinicalTrials.gov; registered start 2026-09, completion 2027-06)

Registry NCT07808060

Women with obesity or overweight

Last verified